Akero SVP Sells $82K in Stock After Options Exercise at $53-55 Range

Insider Trading Activity Report for Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics (AKRO), filed on June 28, 2025, detailing transactions executed on June 16, 2025 under a pre-established Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Insider Trading Activity Report for Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics (AKRO), filed on June 28, 2025, detailing transactions executed on June 16, 2025 under a pre-established Rule 10b5-1 trading plan.

Key Transaction Details:

• Exercised 2,000 stock options at $19.87 per share
• Subsequently sold 2,000 shares in two tranches: - 1,500 shares at weighted average price of $53.82 - 500 shares at weighted average price of $55.09
• Post-transaction holdings: 32,573 shares held directly and 64,182 remaining stock options

The stock options were granted with a 48-month vesting schedule starting December 8, 2023, with expiration in December 2033. All transactions were executed according to a Rule 10b5-1 trading plan established on January 6, 2025, demonstrating planned and compliant insider trading practices.

Insider Trade Summary

Exercise and Sale: 2,000 shares ($69K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Lamy Patrick

Role Senior VP, Commercial Strategy

Sold 2,000 shs ($108K)

Approx. gross sale proceeds $108K

Approx. exercise cost $40K

Approx. pre-tax spread $69K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,000	$0.00	$0.00
Exercise	Common Stock	2,000	$19.87	$40K
Sale	Common Stock	1,500	$53.817	$81K
Sale	Common Stock	500	$55.092	$28K

Holdings After Transaction: Stock Option (Right to Buy) — 64,182 contracts (Direct); Common Stock — 32,573 shares (Direct)

Footnotes (4)

1. F1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 6, 2025, previously adopted by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.52 to $54.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
3. F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.57, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
4. F4. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AKRO's Senior VP Patrick Lamy report on June 16, 2025?

Patrick Lamy exercised 2,000 stock options at $19.87 per share and subsequently sold 2,000 shares in two transactions: 1,500 shares at an average price of $53.817 and 500 shares at an average price of $55.092. These transactions were executed under a Rule 10b5-1 trading plan dated January 6, 2025.

How many AKRO shares does Patrick Lamy own after the reported transactions?

After the reported transactions, Patrick Lamy directly owns 32,573 shares of AKRO common stock and holds stock options for an additional 64,182 shares.

What is the vesting schedule for Patrick Lamy's AKRO stock options?

The stock options vest and become exercisable in 48 equal monthly installments, beginning on December 8, 2023, with an expiration date of December 7, 2033.

What was the profit margin on AKRO SVP Patrick Lamy's June 16, 2025 stock transaction?

Patrick Lamy realized a significant profit by exercising options at $19.87 per share and selling at weighted average prices of $53.817 and $55.092. This represents a profit of approximately $33.95 to $35.22 per share before accounting for taxes and fees.

Was AKRO insider Patrick Lamy's stock sale planned in advance?

Yes, the transactions were executed pursuant to a Rule 10b5-1 trading plan that was established on January 6, 2025, demonstrating these sales were planned approximately 5 months in advance of the actual transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 09:22 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamy Patrick

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BLVD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, Commercial Strategy

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		M(1)		2,000	A	$19.87	34,573	D
Common Stock	06/16/2025		S(1)		1,500	D	$53.817(2)	33,073	D
Common Stock	06/16/2025		S(1)		500	D	$55.092(3)	32,573	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.87	06/16/2025		M(1)			2,000	(4)	12/07/2033	Common Stock	83,182	$0	64,182	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 6, 2025, previously adopted by the Reporting Person.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.52 to $54.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.57, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

4. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023

	/s/ Jonantahn Young, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.